The Epidemiology of Guillain-Barré Syndrome Worldwide

Overview of attention for article published in Neuroepidemiology, December 2008

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
Among the highest-scoring outputs from this source (#11 of 1,011)
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (91st percentile)

Mentioned by

news: 11 news outlets
policy: 3 policy sources
twitter: 3 X users
wikipedia: 1 Wikipedia page

reddit: 1 Redditor
video: 1 YouTube creator
guideline: 1 clinical guideline source
podcasts: 1 podcast

Readers on

mendeley: 393 Mendeley

So far, Altmetric has seen 11 news stories from 11 outlets.

Hansa Biopharma data at the 2025 PNS Annual Meeting demonstrates potential of imlifidase in the treatment of GBS

Crwe World, 14 May 2025

/PRNewswire/ -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), will present data from its 15-HMedIdeS-09 Phase 2 single…

Hansa Biopharma data at the 2025 PNS Annual Meeting demonstrates potential of imlifidase in the treatment of GBS

Press Association, 14 May 2025

/PRNewswire/ -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), will present data from its 15-HMedIdeS-09 Phase 2 single…

Hansa Biopharma data at the 2025 PNS Annual Meeting demonstrates potential of imlifidase in the treatment of GBS

ProfitQuotes.com, 14 May 2025

/PRNewswire/ -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), will present data from its 15-HMedIdeS-09 Phase 2 single…

News story from Finanz Nachrichten on Wednesday 14 May 2025

Finanz Nachrichten, 14 May 2025

This page shows the most recent news stories that mention this research output. Click here to find out how to access more activity, including 7 additional news stories.